Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Thrombotic th" to "[[Acquired thrombotic th") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Thrombotic thrombocytopenic" to "[[Category:Acquired thrombotic thrombocytopenic") |
||
| Line 28: | Line 28: | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category: | + | [[Category:Acquired thrombotic thrombocytopenic purpura medications]] |
[[Category:EMA approved in 2019]] | [[Category:EMA approved in 2019]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Latest revision as of 13:21, 7 June 2023
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2019-02-06: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
History of changes in EMA indication
- 2018-08-30: Initial authorization
History of changes in PMDA indication
- 2022-09-26: A drug with a new active ingredient indicated for the treatment of acquired thrombotic thrombocytopenic purpura.
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi